araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS CLIA

Summary: The primary objective of this study is to substantiate prediction accuracy(with a tighter 95% confidence interval compared to current diagnostic modalities), of a lung cancer biomarker for risk stratification of patients into high and low risk categories to aid in clinical evaluation of the patient.


Eligibility: Inclusion Criteria:
  1. The patient is being evaluated for the diagnosis of possible lung cancer or "rule out lung cancer" and is indicated for bronchoscopy.
  2. The patient is undergoing bronchoscopy
  3. ≥ 21 years of age
  4. Patient meets local site's standard of care (SOC) for performing diagnostic bronchoscopy
  5. The patient is a current or former cigarette smoker (defined as having smoked >100 cigarettes in their lifetime.
  Exclusion Criteria:
  1. The Pulmonary physician does not recommend that bronchoscopy be performed
  2. The patient is unable to be consented into the study or unable to comply with requirements of the study
  3. The patient has previously been diagnosed with primary lung cancer
  4. Immediately prior to bronchoscopy, the patient has been on a mechanical ventilator for ≥ 24 consecutive hours.

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: An Observational Study on Patients With Non-Squamous NSCLC Who Reached A Long PFS After Avastin (Bevacizumab)-Based First-Line Therapy

Summary: This retrospective observational study will analyse demographic, clinical and treatment-related data of patients with non-squamous non-small cell lung cancer (NSCLC) who had reached >/= 9 months of progression-free survival after Avastin (bevacizumab)-based first-line therapy. Data will be collected for approximately 9 months.


Eligibility: Inclusion Criteria:
  -  Adult patients, >/= 18 years of age
  -  Non-squamous non-small cell lung cancer (NSCLC) treated with first-line Avastin-based therapy
  -  Progression-free survival of >/= 9 months reached
  Exclusion Criteria:

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: A Study of TRK-170 for the Treatment of Crohn's Disease

Summary: In Crohn's Disease Patients
  -  To evaluate the efficacy of TRK-170
  -  To evaluate the PK characteristics of TRK-170
  -  To assess the safety of TRK-170


Eligibility: Inclusion Criteria:
  -  Patient has a diagnosis of Crohn's Disease before screening
  -  Patient has stable disease activity
  Exclusion Criteria:
  -  Patient has had a clinically significant illness prior to screening
  -  Patient with clinically significant deviations in laboratory values

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: 10 Prescriptions an Hour. Group Treatment and Physical Activity Referral in a Primary Health Care Setting

Summary: The purpose of this study is to determine the effects of group treatment including physical activity referral (PAR) on level of physical activity and quality of life in patients diagnosed with type 2 diabetes and/or hypertension in a primary health care setting

Detailed description: A sedentary lifestyle and low levels of physical activity in populations are major health problems today and contribute substantially to poor health and diseases such as type 2 diabetes and hypertension. An increased and systematic effort to increase physical activity in the Swedish population in general, and in patients with type 2 diabetes/hypertension in particular, is important. Written prescriptions of physical activity with follow-up (i.e., PAR), is a cost-efficient way to increase physical activity in individuals.
  The aim of this trial is to study whether physical activity is increased by a group method involving PARs in patients with hypertension and/or type 2 diabetes compared with a control group that receives usual care in the same primary care setting. Follow-up will be performed at 6 and 12 months.
  This trial is being conducted to determine whether it is possible to offer PARs to more patients in a way that requires less effort and resources. The intervention in this study requires 10 minutes of a health care worker's time per patient during a 6-month period. Each patient requires 100 minutes with an instructor who oversees the group intervention.
  Group treatment is given 3 weeks after baseline and at 6 months. Follow-up at 12 months involves data collection, but no intervention.
  An empowerment process, with the 5-A-model as framework, will be used in the clinical intervention.
  All participants will be required to fill in questionnaires and wear an ActiGraph GTM1/GTM3 for 7 days at baseline and at 6 and 12 months.

Eligibility: Inclusion Criteria:
  -  Clinical diagnosis of hypertension or type 2 diabetes since 10-09-2009 at St Hans Primary Health Care Center, Lund, Sweden
  Exclusion criteria:
  -  Dementia
  -  Psychosis
  -  Drug abuse
  -  Mental retardation
  -  Inability to walk without assistance
  -  Inability to speak Swedish

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Psychological and Physical Distress and Care Needs in Operable Lung Cancer Patients Receiving Surgery

Summary: The lung cancer is the most has the life minacity in all kinds of cancers, and it also remains the most common cause of cancer-related death in the world. The group of lung cancer patients are suffer from huge disease impact that came from high mortality. Not only the course of treatment that patients has been diagnosis through operation is more faster, but also those who could be capable of operated are stabilized to keep follow-up at out-patient clinic. But in the next following five years after operation, they may take different dysfunctional level or some kinds of symptom distress. The effect has a great influence on those patients that have to face extended emotional impact, symptom distress and life style change. In addition, most of them concern about recurrent all the time in the remission. These situation needs us to place importance on it.
  The purposes of this study are to investigate psychological and physical distress and care needs in operable lung cancer patients receiving surgery. This survey includes two parts of physical and mental condition. First, the investigators are scoring their symptom severity and quality of life to check physical condition. Seconded, the mental condition will use validated questionnaires to realize the relationship of anxiety, depression, uncertainty, fear of recurrence, self-efficacy and needs. Final, compare all of the data to patients' needs.
  This study is a cross-sectional designs with convenience sampling that conform to the investigators recruited requirements. The investigators will recruit from the clinic of thoracic surgery in one medical center in Taipei and take five structured requirements. And the investigators are going to collect data from January, 2011 to December, 2012. Also expect results are lung cancer outpatients after surgery that more physical dysfunction or more depress of mental condition, it will lead patients' needs increased or significant difference. In conclusion, this study analyzes their needs in the remission that consequences can be medical professionals' reference material.

Detailed description: Inclusion Criteria:
  lung cancer patients after surgery stage I, II and IIIA surgery for 3 months to 5 years over 20 years old
  Exclusion Criteria:
  lung cancer recurrence conscious unclear and do not know having cancer used to be treat (surgery, chemotherapy or radiotherapy) in 3 months. be uncomfortable or cooperate to fill the questionnaire.

Eligibility: Inclusion Criteria:
  -  lung cancer patients after surgery
  -  stage I, II and IIIA
  -  surgery for 3 months to 5 years
  -  over 20 years old
  Exclusion Criteria:
  -  lung cancer recurrence
  -  conscious unclear and do not know having cancer
  -  used to be treat (surgery, chemotherapy or radiotherapy) in 3 months.
  -  be uncomfortable or cooperate to fill the questionnaire.

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Safety Evaluation of Dexmedetomidine for EBUS-TBNA

Summary: Lung cancer is the second most commonly diagnosed primary neoplasia in Canada accounting for 22 865 new cases in 2007. Recent randomized trials have shown a significantly better diagnostic yield and fewer unnecessary thoracotomies with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) when compared to conventional TBNA for various clinical conditions including peripheral pulmonary lesions and sarcoidosis. EBUS-TBNA are now routinely performed in our institution for staging of pulmonary and mediastinal cancer. EBUS-TBNA are performed under monitored anesthesia care (MAC) in the endoscopy suite at the Centre de soins ambulatoires of the Hôpital Maisonneuve-Rosemont.
  Remifentanil, used in combined regime or as single agent proved to be effective and safe for MAC. Nonetheless, anesthesiologists are still confronted to the respiratory depression profile of remifentanil and other commonly used agents. An analysis of the ASA Closed Claims demonstrated that respiratory depression remains a significant drawback during MAC in remote locations. Furthermore, patients with coexisting pulmonary diseases scheduled for EBUS-TBNA are at increased risk of such complications.
  The investigators hypothesize that compared to the use of remifentanil-based MAC protocol, the use of dexmedetomidine-based MAC protocol for EBUS-TBNA will result in a lower incidence of major respiratory and hemodynamic adverse events (bradypnea, apnea, oxygen desaturation, hypotension, hypertension, bradycardia and tachycardia) with equivalent overall procedure conditions.

Detailed description: See above

Eligibility: Inclusion Criteria:
  -  Subjects with planned EBUS-TBNA under conscious sedation.
  -  Age 18-75 years old.
  -  American Society of Anesthesiologists class I-III.
  -  The subject is able to understand the study objectives, the experimental protocol and procedures, and is capable of providing an informed consent.
  Exclusion Criteria:
  -  Subjects allergic to any of the study drugs.
  -  BMI > 34 kg/m2.
  -  Severe renal or hepatic failure.
  -  Pregnancy.
  -  Emergent procedure.
  -  Heart failure NYHA > III.
  -  Systolic blood pressure < 90 mmHg.
  -  Advanced heart block (unless patient has a pacemaker).
  -  Unstable angina and/or myocardial infarction within past 6 weeks.
  -  FEV1 ≤ 0.8 L.
  -  Oxygen-dependent patient.
  -  Use of α2-adrenoreceptor agonist or antagonist within 14 days.

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Distinction Between Lung Cancer and Gynecological Cancers by Canine Scent Detection

Summary: Previous studies have shown that specially trained sniffer dogs are capable to discriminate breath samples of patients with lung cancer and healthy individuals. So far it is not known whether this differentiation is specific for lung cancer or just identifies any form of (solid) tumor. Therefore, the dog's ability to differentiate between lung cancer, breast cancer and ovarian cancer is tested.


Eligibility: Inclusion Criteria:
  -  histologically confirmed lung or breast or ovarian cancer
  Exclusion Criteria:
  -  other cancers
  -  previous medical intervention within the last 14 days before gathering of the breath sample

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Recovery and Rehabilitation After Lung Cancer Surgery

Summary: The specific aims of this translational, interdisciplinary, multi-center, international research study with 300 Lung cancer patients are to:
  Aim 1 Explore how the patients experience the transfer between different locations and between different levels of care at the same location and how they experienced coming home.
  Aim 2 Explore lung cancer patients' symptoms, symptom clusters, and changes in symptoms and symptom clusters over time.
  Aim 3 Explore interaction between lung cancers patients' symptoms, symptom clusters, health related quality of life and social support.

Detailed description: Approximately 2500 patients are diagnosed with lung cancer annually i Norway, and approximately 400 of these undergo surgery. Many patients report that life after lung cancer surgery is difficult. After surgery, the patients are frequently transferred to a local hospital or to another level of care at the hospital where they were operated. The transfer is critical for patients' safety because communication failure is one of the most common causes of medical error.
  Studies that have analyzed the quality of life of lung cancer patients after surgery reach different conclusions about the patients' Quality of life (QOL), some studies state that lung cancer patients are back to normal quality of life after 9 months, while others indicate that the patients still have reduced QOL two years after surgery. It is difficult to assess the reason for the differences in results as most of the studies used the same QOL questionnaire. Studies that have evaluated the social support that lung cancer patients receive indicate that lung cancer patients receive less support than other cancer patients.
  Lung cancer patients have a wide range of physical problems (fatigue, dyspnea, coughing and pain) and psychological (depression) problems following surgery.
  Based on findings from this literature review a need exist for improved postoperative follow-up of patients after surgery for lung cancer The proposed study will evaluate the social support, the levels of lung cancer stigma, symptoms and changes in this over time as well as evaluate patient experience with transfer in the immediate postoperative period.

Eligibility: Inclusion Criteria:
  -  patients with lung cancer patients above the age of 18 that have been treated with surgery, who are able to speak and understand Norwegian,
  Exclusion Criteria:
  -  and who suffer no cognitive impairment.

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Postoperative Results of Surgical Treatment of Lung Cancer After 30 Days

Summary: This is a retrospective, descriptive analysis of (1) 30 day postoperative results of surgery for lung cancer, (2) 30 day outcome predictors - compared to an earlier similar study in the same hospital (St Olav University Hospital, Trondheim, Norway).


Eligibility: Inclusion Criteria:
  -  Lung cancer patients after surgery in 2002-2004 at dept for Heart and Lung Surgery, St.Olavs University Hospital, Trondheim, Norway.
  Exclusion Criteria:
  -  Carcinoid tumor, small-cell lung cancer, lung metastases

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC)

Summary: Gemcitabine, docetaxel, CPT-11 and cisplatin are effective in 1st line treatment of advanced non-small cell lung cancer (NSCLC). Platinum-based doublets including gemcitabine, docetaxel or CPT-11 are standard 1st regimens. BRCA1 and RRM1 expression levels are reported to be associated with sensitivity of the tumor cells to cytotoxic agents. Some Phase II or III trials did prove feasibility of customized chemotherapy based upon expression levels of one or two biomarkers in the NSCLC patients. The investigators think customized chemotherapy may further improve efficacy of chemotherapy in advanced NSCLC. But there is no randomised trial to compare efficacy of standard chemotherapy with individualized chemotherapy in this setting. So, the investigators plan to initiate this phase II trial to compare efficacy between standard chemotherapy of gemcitabine/cisplatin versus customized chemotherapy in chemonaive NSCLC patients.

Detailed description: Primary end point:ORR Secondary end point:PFS,OS,safety,QOL,etc.

Eligibility: Inclusion Criteria:
  1. Written informed consent,
  2. Histologically confirmed stage M1a or M1b NSCLC,
  3. Aged over 18 years old,
  4. Measurable disease,
  5. Life expectancy of at least 12 weeks,
  6. No prior chemotherapy or target therapy,
  7. No brain metastases or spinal cord compression,
  8. Less than 10% body weight loss,
  9. ECOG performance status 0-2,
  10. Adequate vital organ function (haematological, renal, hepatic, etc).
  11. Enough tissue for detection of BRCA1 and RRM1 expression.
  Exclusion Criteria:
  1. Prior systemic cytotoxic chemotherapy or EGFR TKI therapy,
  2. Positive pregnancy test,
  3. Another active malignancy, other than superficial basal cell and squamous cell or carcinoma in situ of the cervix, within the last 5 years,
  4. Patients with brain metastases or spinal cord compression,
  5. Allergy to gemcitabine, cisplatin, docetaxel, CPT-11,
  6. Any unstable systemic disease including active infection,
  7. No enough tissue for detection of BRCA1 and RRM1

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment

Summary: The PK and safety profiles to be examined following a single oral administration of TRK-100STP (120 μg) under fasting conditions to patients with renal impairment and to subjects with normal renal function.


Eligibility: Inclusion Criteria:
  -  The eGFR 1 day before study drug administration are stipulated as follows.
  -  Subjects with normal renal function : ≥90
  -  Patients with mild renal impairment : ≥60 to <90
  -  Patients with moderate renal impairment : ≥30 to <60
  -  Patients with severe renal impairment : ≥15 to <30
  Exclusion Criteria:
  -  Patients on dialysis
  -  Patients who have a history of undergoing renal transplantation
  -  Patients with diabetes mellitus

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

Summary: This study examines preoperative Erlotinib in patients with operable stage II and IIIA Non-small-cell lung cancer (NSCLC) harboring EGFR mutations.

Detailed description: Lung cancer remains the most common cause of cancer-related death in the world. Non-small-cell lung cancer (NSCLC) is the most common type, and it accounts for 85% of cases. Unfortunately, the majority of patients with NSCLC have metastatic disease at diagnosis. However, even patients with resectable disease have poor survival. The need to improve survival rates in these patients prompted research exploring the role of systemic therapy in operable NSCLC. In the 1990s, several clinical trials of preoperative chemotherapy (also known as induction chemotherapy) followed by surgery or radiation in patients with locally advanced NSCLC showed improvements in survival. Erlotinib is an orally administered tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR). The presence of somatic mutations in the kinase domain of EGFR strongly correlates with increased responsiveness to EGFR tyrosine kinase inhibitors. Recently three randomized phase III trials showed that first-line use of EGFR-TKIs in patients with EGFR mutant NSCLC significantly improved response rate and progression-free survival (PFS) compared to platinum-based chemotherapy. These findings prompted this phase II trial of preoperative Erlotinib in patients with operable stage II and IIIA NSCLC harboring EGFR mutations.

Eligibility: Inclusion Criteria:
  -  Pathologically confirmed stage II & IIIA non-small cell lung cancer
  -  EGFR exon 19 or 21 mutations
  -  Age ≥ 18 years and ECOG performance 0~1
  -  Has measurable lesion by RECIST 1.1
  -  No previous chemotherapy or radiation therapy
  -  Adequate organ function by following; ANC ≥1,500/uL, hemoglobin ≥9.0g/dL, platelet ≥100,000/uL, PaO2 ≥ 60 mmHg, Serum Cr < 1 x UNL or creatinine clearance > 60 ml/min, Serum bilirubin < 1 x UNL, AST (SGOT) and ALT (SGPT) < 2.5 x UNL, alkaline phosphatase < 5 x UNL
  -  Written informed consent form
  Exclusion Criteria:
  -  Previous chemotherapy or radiation therapy
  -  Previous history of malignancy within 5 years from study entry except treated non-melanomatous skin cancer or uterine cervical cancer in situ
  -  Known allergic history of erlotinib
  -  Interstitial lung disease or fibrosis on chest radiogram
  -  Active infection, uncontrolled systemic disease (cardiopulmonary insufficiency, fatal arrhythmias, hepatitis)
  -  Pregnant or nursing women

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)

Summary: This project proposes to use bronchoscopic intratumoral chemotherapy for small cell lung cancer in two fashions:
  1. to implement a prospective clinical trial to test the feasibility and efficacy of intralesional chemotherapy as consolidative therapy immediately following standard systemic chemotherapy and radiation therapy for patients with limited stage SCLC by comparing tumor growth and survival rates of the treatment group and compare the outcomes to historical controls
  2. to implement a prospective clinical trial to test the feasibility and efficacy as measured by tumor growth and survival rates of intralesional chemotherapy for patients with recurrent SCLC after standard treatment.

Detailed description: Subjects will receive standard of care treatment for SCLC with added treatment of Cisplatin injection via endobronchial ultrasound aided bronchoscopy a total of four times. Outcome measurements of tumor growth and survival will be compared to subjects receiving standard of care treatment only.

Eligibility: Inclusion Criteria: Competent adult English speaking subjects
  -  With limited stage SCLC who have completed standard of care treatment who are responders with no evidence of disseminated disease other than CNS metastasis,
  -  With recurrent disseminated SCLC after standard of care treatment with symptoms related to central tumor obstruction,
  -  With recurrent limited stage SCLC with mediastinal/hilar recurrence not previously treated with intratumoral cisplatin
  Exclusion Criteria:
  -  Subjects who do not meet the inclusion criteria
  -  Subjects who, in the opinion of the investigator, are at risk undergoing a bronchoscopy

Relevance to patient case: not relevant